A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine
H. Lundbeck A/S
315 participants
Jun 8, 2023
INTERVENTIONAL
Conditions
Summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Solution for infusion
Solution for infusion
Locations(65)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05897320